Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Hepcidin and ferritin levels as markers of immune cell activation during septic shock, severe COVID-19 and sterile inflammation

M. Hortová-Kohoutková, M. Skotáková, IG. Onyango, M. Slezáková, R. Panovský, L. Opatřil, P. Slanina, M. De Zuani, O. Mrkva, I. Andrejčinová, P. Lázničková, M. Dvončová, A. Mýtniková, V. Ostland, M. Šitina, GB. Stokin, V. Šrámek, M. Vlková, M....

. 2023 ; 14 (-) : 1110540. [pub] 20230127

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004498

INTRODUCTION: Major clinically relevant inflammatory events such as septic shock and severe COVID-19 trigger dynamic changes in the host immune system, presenting promising candidates for new biomarkers to improve precision diagnostics and patient stratification. Hepcidin, a master regulator of iron metabolism, has been intensively studied in many pathologies associated with immune system activation, however these data have never been compared to other clinical settings. Thus, we aimed to reveal the dynamics of iron regulation in various clinical settings and to determine the suitability of hepcidin and/or ferritin levels as biomarkers of inflammatory disease severity. COHORTS: To investigate the overall predictive ability of hepcidin and ferritin, we enrolled the patients suffering with three different diagnoses - in detail 40 patients with COVID-19, 29 patients in septic shock and eight orthopedic patients who were compared to nine healthy donors and all cohorts to each other. RESULTS: We showed that increased hepcidin levels reflect overall immune cell activation driven by intrinsic stimuli, without requiring direct involvement of infection vectors. Contrary to hepcidin, ferritin levels were more strongly boosted by pathogen-induced inflammation - in septic shock more than four-fold and in COVID-19 six-fold in comparison to sterile inflammation. We also defined the predictive capacity of hepcidin-to-ferritin ratio with AUC=0.79 and P = 0.03. DISCUSSION: Our findings confirm that hepcidin is a potent marker of septic shock and other acute inflammation-associated pathologies and demonstrate the utility of the hepcidin-to-ferritin ratio as a predictor of mortality in septic shock, but not in COVID-19.

000      
00000naa a2200000 a 4500
001      
bmc23004498
003      
CZ-PrNML
005      
20230425141441.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2023.1110540 $2 doi
035    __
$a (PubMed)36776891
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hortová-Kohoutková, Marcela $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
245    10
$a Hepcidin and ferritin levels as markers of immune cell activation during septic shock, severe COVID-19 and sterile inflammation / $c M. Hortová-Kohoutková, M. Skotáková, IG. Onyango, M. Slezáková, R. Panovský, L. Opatřil, P. Slanina, M. De Zuani, O. Mrkva, I. Andrejčinová, P. Lázničková, M. Dvončová, A. Mýtniková, V. Ostland, M. Šitina, GB. Stokin, V. Šrámek, M. Vlková, M. Helán, J. Frič
520    9_
$a INTRODUCTION: Major clinically relevant inflammatory events such as septic shock and severe COVID-19 trigger dynamic changes in the host immune system, presenting promising candidates for new biomarkers to improve precision diagnostics and patient stratification. Hepcidin, a master regulator of iron metabolism, has been intensively studied in many pathologies associated with immune system activation, however these data have never been compared to other clinical settings. Thus, we aimed to reveal the dynamics of iron regulation in various clinical settings and to determine the suitability of hepcidin and/or ferritin levels as biomarkers of inflammatory disease severity. COHORTS: To investigate the overall predictive ability of hepcidin and ferritin, we enrolled the patients suffering with three different diagnoses - in detail 40 patients with COVID-19, 29 patients in septic shock and eight orthopedic patients who were compared to nine healthy donors and all cohorts to each other. RESULTS: We showed that increased hepcidin levels reflect overall immune cell activation driven by intrinsic stimuli, without requiring direct involvement of infection vectors. Contrary to hepcidin, ferritin levels were more strongly boosted by pathogen-induced inflammation - in septic shock more than four-fold and in COVID-19 six-fold in comparison to sterile inflammation. We also defined the predictive capacity of hepcidin-to-ferritin ratio with AUC=0.79 and P = 0.03. DISCUSSION: Our findings confirm that hepcidin is a potent marker of septic shock and other acute inflammation-associated pathologies and demonstrate the utility of the hepcidin-to-ferritin ratio as a predictor of mortality in septic shock, but not in COVID-19.
650    _2
$a lidé $7 D006801
650    12
$a septický šok $7 D012772
650    _2
$a hepcidiny $x metabolismus $7 D064451
650    12
$a COVID-19 $7 D000086382
650    _2
$a železo $x metabolismus $7 D007501
650    _2
$a ferritin $7 D005293
650    _2
$a zánět $7 D007249
650    _2
$a biologické markery $7 D015415
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Skotáková, Monika $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Onyango, Isaac G $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Slezáková, Miriam $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Panovský, Roman $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u 1st Department of Internal Medicine/Cardioangiology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Opatřil, Lukáš $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u 1st Department of Internal Medicine/Cardioangiology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Slanina, Peter $u Institute of Clinical Immunology and Allergology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a De Zuani, Marco $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Mrkva, Ondřej $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Andrejčinová, Ivana $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Lázničková, Petra $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
700    1_
$a Dvončová, Martina $u Department of Anesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Mýtniková, Alexandra $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u Department of Anesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Ostland, Vaughn $u Intrinsic Lifesciences, La Jolla, CA, United States
700    1_
$a Šitina, Michal $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u Department of Anesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Stokin, Gorazd B $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u Celica BIOMEDICAL, Ljubljana, Slovenia $u Division of Neurology, University Medical Centre, Ljubljana, Slovenia
700    1_
$a Šrámek, Vladimír $u Department of Anesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Vlková, Marcela $u Institute of Clinical Immunology and Allergology, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Helán, Martin $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u Department of Anesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Frič, Jan $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czechia $u Department of Modern Immunotherapy, Institute of Hematology and Blood Transfusion, Prague, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 14, č. - (2023), s. 1110540
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36776891 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141437 $b ABA008
999    __
$a ok $b bmc $g 1924916 $s 1190707
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1110540 $e 20230127 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace